Old Web
English
Sign In
Acemap
>
Paper
>
DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
DOP62 Immunogenicity to second anti-TNF therapy (IMSAT): Implications for sequencing of biologic therapy
2021
Neil Chanchlani
Imsat study investigators
Simeng Lin
Amanda Thomas
Ben Hamilton
Rachel Nice
D. Chee
N A Kennedy
J. Goodhand
Tariq Ahmad
Keywords:
Infliximab
Medicine
Immunology
Immunogenicity
Inflammatory bowel disease
Anti-Tumor Necrosis Factor Therapy
Irritable bowel syndrome
Crohn's disease
Adalimumab
Pharmacodynamics
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]